TRVI — Trevi Therapeutics, Inc.

Trevi Therapeutics (TRVI) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Trevi ended 2025 with approximately $188 million in cash, cash equivalents, and marketable securities, providing a runway into 2028.
• This financial position supports upcoming clinical trials and key data readouts, including pivotal Phase III trials for IPF-related chronic cough.

2. Strategic Updates and Business Highlights

• Trevi reported positive data from the CORAL and RIVER trials, which has driven growth and capital raising efforts.
• The company received constructive feedback from the FDA during an End-of-Phase 2 meeting regarding its IPF-related chronic cough program, confirming the path forward for NDA submission.
• Plans include initiating two pivotal Phase III trials for IPF-related chronic cough in Q2 2026 and Q3 2026, with a focus on patient safety and efficacy.
• An adaptive Phase IIb trial for non-IPF ILD-related chronic cough is planned for Q3 2026, potentially doubling the market opportunity.
• A Phase IIb trial for refractory chronic cough is also scheduled for initiation in Q2 2026.

3. Forward Guidance and Outlook

• Trevi aims to maintain momentum by initiating clinical trials and expects to provide top-line data from key studies in the coming years.
• The company is preparing for an Investor and Analyst Day in May 2026, where it will discuss clinical timelines and commercial strategies in detail.
• There is optimism about the potential to be the first approved therapy for IPF-related chronic cough, addressing a significant unmet need.

4. Bad News, Challenges, or Points of Concern

• The requirement for a 52-week controlled safety data set means that the 24-week endpoint for the IPF trial will not be available until the end of the study, potentially delaying insights and impacting cash flow planning.
• The need for additional Phase I drug-drug interaction studies may arise depending on the timing of approvals for competing IPF drugs.
• The FDA's evolving stance on drug scheduling and the potential for increased regulatory scrutiny could pose risks to the approval process.

5. Notable Q&A Insights

• Management confirmed that the secondary endpoints in the Phase III trials will include patient-reported outcomes (PROs) related to cough frequency and severity, as well as breathlessness.
• There was a discussion about the placebo effect in the longer 24-week trial, with historical data suggesting a 17% placebo response.
• The company is focused on ensuring that the patient population for the trials is as real-world as possible, including patients on background antifibrotic medications and without strict cough count requirements.
• There is confidence that the drug will remain unscheduled, based on ongoing discussions with the FDA regarding its abuse potential.

Overall, Trevi Therapeutics is positioned for significant clinical advancements in the chronic cough market, with a clear strategic focus and a solid financial foundation, despite some regulatory and operational challenges ahead.